Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques

European Heart Journal

Volumn 23, Issue 21, 2002, Pages 1664-1669

  Stefanadis, C ^a,b   Toutouzas, K ^a   Vavuranakis, M ^a   Tsiamis, E ^a   Tousoulis, D ^a   Panagiotakos, D B ^a   Vaina, S ^a   Pitsavos, C ^a   Toutouzas, P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Atherosclerotic plaque; Inflammation; Statins; Temperature

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; STATINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEAT TRANSFER; HUMAN; IN VIVO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TEMPERATURE; THERMAL ANALYSIS; THERMOGRAPHY; UNSTABLE ANGINA PECTORIS;

EID: 0036869136     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3174     Document Type: Article

References (30)

1. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
2. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
3. Koenig W, Sund M, Froelich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsberg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
4. Tracy R, Lemaitre R, Psaty B et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardio-vascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.
5. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses, BMJ 2000; 321: 199-204.
6. Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
7. The Long Term Intervention with Pravastatin in Ischemic Heart Disease (Lipid) Study Groups. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
8. The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Expert Panel Report of the National Cholesterol Education Program. Arch Intern Med 1986; 148: 36-9.
9. The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015-23.
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
11. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
12. Shepherd J, Cobbe SM, Ford I et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333: 1301-7.
13. Downs JR, Clearfield M, Weis S et al. For the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615-22.
14. Casscells W, Hathorn B, David M et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet 1996; 347: 1447-9.
15. Stefanadis C, Toutouzas P. In vivo local thermography of coronary artery atherosclerotic plaques in humans. Ann Intern Med 1998; 129: 1079-80.
16. Stefanadis C, Diamantopoulos L, Vlachopoulos C et al. Thermal Heterogeneity Within Human Atherosclerotic Coronary Arteries Detected In Vivo: A new method of detection by application of a special thermography catheter. Circulation 1999; 99: 1965-71.
17. Stefanadis C, Toutouzas K, Tsiamis E, Vavuranakis M, Kallikazaros I, Toutouzas P. Thermography of human arterial system by means of new thermography catheter. Cathet Cardiovasc Intervent 2001; 54: 51-8.
18. Stefanadis C, Diamantopoulos L, Dernellis J et al. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol 2000; 32: 43-52.
19. Stefanadis C, Toutouzas K, Tsiamis E et al. Increased local temperature in human coronary atherosclerotic plaques: An independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention. J Am Coll Cardiol 2001; 37: 1277-83.
20. Ridker MP, Hennekens CH, Roitman-Johnson B et al. Plasma concentration of soluble intercellular adhesion molecule I and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
21. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease, Lancet 1999; 353: 118-19.
22. For the Cholesterol, and Recurrent Events (CARE) Investigators, Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
23. For the Cholesterol, and Recurrent Events (CARE) Investigators, Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
24. Pocock SJ. Clinical Trials: a practical approach. New York: John Wiley & Sons Ltd. 1998: 80-7.
25. Weber C, Erl W, Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CDllbdependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-17.
26. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997; 17: 1521-6.
27. Bustos C, Hernandez-Presa MA, Ortego M et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-64.
28. Jialal I, Stein D, Balis D et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5.
29. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3.
30. Schoenhagen P, Ziada KM, Vince DG, Nissen SE, Tuzcu EM. Arterial remodeling and coronary artery disease: the concept of 'dilated' versus 'obstructive' coronary atherosclerosis. J Am Coll Cardiol 2001; 38: 297-306.